Senses Disorder TRIZ Cases

Local AAV-mediated IL-18 expression suppresses choroidal neovascularization while avoiding systemic inflammation risks associated with antibody therapies.

Isolating the 2S,4R ketoconazole enantiomer reduces adverse side effects and liver damage risks associated with racemic mixtures.

Specific heterocyclic compounds inhibit Retinol Binding Protein 4 binding to reduce blood concentrations.

Substituted 4-pyridones inhibit neutrophil elastase to treat chronic inflammatory diseases while maintaining metabolic stability.

Engineered antibodies incorporate monomeric IL10 into complementarity determining regions, extending half-life and reducing pro-inflammatory activity.

Interfering RNA silences Syk mRNA to reduce protein levels, avoiding systemic antihistamine side effects.

Saponification and partial isomerization of plant extracts yield high-concentration trans-lutein and zeaxanthin isomers in a precise 4:1 to 6:1 ratio.

Zeaxanthin supplementation increases macular pigment optical density, reducing photostress recovery time for athletes under challenging lighting conditions.

Thrombin peptide derivatives activate non-proteolytically activated receptors to inhibit apoptosis and delay disease progression in degenerative disorders.

Valdecoxib inhibits endoplasmic reticulum stress via the PERK-ATF4-CHOP pathway, reversing retinal ganglion cell loss in glaucoma models.

N-phenyl carbamate derivatives modulate the formyl peptide 2 receptor, addressing side effects from steroids and NSAIDs in ocular inflammation.

A pharmaceutical composition containing VCP inhibitors protects corneal endothelial and epithelial cells from damage.

A composition combining Coccinia grandis stem juice with cooked goat liver provides high vitamin A concentrations.

Thiophene-based glucagon receptor antagonists reduce hyperglycemia by blocking hepatic glucose production without causing hypoglycemia.

A terpenoid derivative activates the Keap1/Nrf2/ARE signaling pathway to induce cytoprotective effects.

Liposomal microRNA-195 reduces blood vessel permeability and inflammation without intraocular injection complexity.

Intrathecal cerebrospinal fluid infusion boosts glymphatic waste removal, offering an alternative to ineffective glaucoma therapies with fewer side effects.

Immobilized ligands bind fibrogenic cytokines on an ophthalmic implant surface, preventing posterior capsule opacification.

LNA-modified antisense oligonucleotides target TGF-beta mRNA sequences to suppress gene expression in ophthalmic treatments.

Antioxidant nanoparticles deliver ubiquinol and SOD2 mimetics to corneal tissue, reducing oxidative stress damage during preservation.

A temperature-responsive polymer coating enables non-enzymatic detachment of cell sheets while maintaining high hyaluronic acid production.

Cardiosphere-derived exosomes resolve alkali burns and GVHD by modulating inflammation while enhancing tissue regeneration.

A short synthetic peptide sequence treats dry eye syndrome and psoriasis by enhancing tear production and reducing inflammation.

Hyaluronic acid matrices stabilize autologous cell grafts at the point of care, eliminating culture steps that cause contamination and non-adherent cell loss.

A topical biotherapeutic composition of sour cherry seed extract and oil induces heme oxygenase-1 activity in leukocytes.

Fully human anti-BTLA antibodies eliminate immunogenicity while maintaining BTLA binding activity for repeated administration.

N-terminal proline derivatives enable stable alpha-helix nucleating staples via olefin metathesis crosslinking.

Converting amorphous crude material into a stable crystalline phase resolves hygroscopicity and low purity bottlenecks in pharmaceutical manufacturing.

A plasma generating device creates therapeutic ophthalmic solutions using non-thermal equilibrium plasma.

Formula I benzoxazole compounds inhibit specific sodium channel isoforms.

Terminalia chebula extract reduces corneal damage and inflammation while avoiding side effects from synthetic anti-inflammatory agents.

Split-inteins mediate protein trans-splicing to reconstitute large polypeptides, bypassing AAV cargo limits and stabilizing expression for genes exceeding 5 kb.

An EP2-selective pyridylaminoacetic acid compound lowers intraocular pressure by enhancing aqueous humor drainage, avoiding FP receptor side effects.

Curved housing surfaces eliminate tortuous flow paths to reduce pressure drop while enhancing mixing efficiency for dissolved oxygen retention.

Liposomal delivery restores membrane fatty acid ratios and inhibits lipid peroxidation, addressing root causes of inflammatory diseases.

Spiro-lactam compounds modulate NMDA receptors to treat CNS disorders while enhancing binding specificity and oral bioavailability.

Biodegradable intracameral implants release therapeutic agents into the anterior chamber to maintain steady drug concentrations.

Phenylacetamide compound activates hepatic glucokinase to lower blood glucose levels while reducing hypoglycemia risk.

A pharmaceutical composition containing Substance-P modulates immune cell populations to treat inflammatory conditions.

A bispecific binding molecule scavenges VEGF and activates TrkB signaling.

Synp162 promoter overcomes low specificity of standard viral promoters by combining regulatory elements with strong transcriptional cores.

Cyclodextrin inclusion complexes enable aqueous delivery of poorly soluble neuroprotective agents, resolving ocular tissue penetration barriers.

4-substituted phenoxyphenylacetic acid derivatives modulate the DP2 receptor to treat allergic inflammation.

A Klotho fusion polypeptide combines alpha-Klotho with FGF23 and a modified Fc fragment to enhance serum half-life.

Semifluorinated alkane vehicle suspends nebivolol to resolve vision impairment and microbial contamination in glaucoma treatment.

Isotopically modified polyunsaturated fatty acids stabilize oxidation-prone bonds to protect retinal tissue from reactive oxygen species.

Local niclosamide delivery targets intestinal mucosa, inducing pathogenic T cell death while avoiding systemic toxicity.

Pre-treated stem cells enhance CXCR4 expression to improve homing efficiency.

Small molecule TrkA agonists deliver neurotrophic support to retinal ganglion cells, addressing manufacturing challenges of recombinant proteins.